The BV poster, Masterlongevity, posted that having a separate unblinded consultant for verification purposes was standard procedure in double blinded trials. However, Garnick was the regulatory architect for PPHM in the 2nd line trial and is probably as well-versed in clinical trial design as most BV posters. Do you find it curious that Garnick wouldn't put such a "basic" safeguard in place?
Market Data 
Markets 
AI
